MedTrace Logo

Reducing the Harmful Effects of Cannabis Use: Finding the Optimal CBD:THC Ratio

NCT05170217 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2021-12-27

No results posted yet for this study

Summary

This study will recruit healthy volunteers who use cannabis infrequently. Each participant will attend the laboratory on five occasions: an initial visit to check that they are safe to join the study and four days of testing.

Participants will be administered, in a randomized order, vaporized cannabis containing one of four different ratios of CBD:THC (0:1, 1:1, 2:1, 3:1). The cannabis administration will follow a standardised inhalation procedure using a medical-grade vaporizer device.

Participants will complete a series of tasks measuring cognition, psychosis, anxiety and other subjective experiences.

The study will be carried out at the NIHR-Wellcome Trust Clinical Research Facility at King's College Hospital.

Conditions

  • Cannabis Use

Interventions

DRUG

THC

Inhaled cannabis containing 10mg THC

DRUG

Cannabidiol

Inhaled cannabis containing 10mg CBD

DRUG

Cannabidiol

Inhaled cannabis containing 20mg CBD

DRUG

Cannabidiol

Inhaled cannabis containing 30mg CBD

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-11-08
Primary Completion
2019-06-09
Completion
2019-06-09

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05170217 on ClinicalTrials.gov